/
Metabolic & Endocrine
Type 2 Diabetes
206
Pipeline Programs↗
442
Active Trials↗
192
Companies Involved↗
Type 2 Diabetes is a highly competitive landscape with 206 programs across 192 companies. The most active players are Eli Lilly, Novo Nordisk, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.. 49 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical120
Phase 115
Phase 222
Phase 349
Approved
No programs
Analysis
Modality Breakdown
97%
Small molecule
185 of 190 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 190 classified programs, each share of the total. Modality classified for 95% of 206 pipeline programs.
Analysis
Trial Status
3,096
clinical trials
Completed2,198 · 71%
Unknown status203 · 7%
Recruiting197 · 6%
Terminated183 · 6%
Not yet recruiting124 · 4%
Active, not recruiting102 · 3%
Other89 · 3%
Clinical Trials
Trial Activity
3096 trials
The Cognitive Protective Effect of VR-based Cognitive Training in Type 2 Diabetes Patients With Mild Cognitive Impairment：A Prospective, Randomized, Open-Label, Parallel-Group Pilot Study
Recruiting·TThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School·Preclinical·NCT07650318·40 enrolled
Involvement of Muscle Mitochondrial Dysfunction in Frailty in Older Adults. Role of Exercise
Recruiting·FFundación para la Investigación del Hospital Clínico de Valencia·Preclinical·NCT07828847·120 enrolled
Page 1 of 207
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)